Search Results - "Cheung, Lawrence H."

Refine Results
  1. 1

    Production of Recombinant Gelonin Using an Automated Liquid Chromatography System by Berstad, Maria E B, Cheung, Lawrence H, Weyergang, Anette

    Published in Toxins (13-08-2020)
    “…Advances in recombinant DNA technology have opened up new possibilities of exploiting toxic proteins for therapeutic purposes. Bringing forth these protein…”
    Get full text
    Journal Article
  2. 2

    Development of a human immuno-oncology therapeutic agent targeting HER2: targeted delivery of granzyme B by Cheung, Lawrence H, Zhao, Yunli, Alvarez-Cienfuegos, Ana, Mohamedali, Khalid A, Cao, Yu J, Hittelman, Walter N, Rosenblum, Michael G

    “…Immunotherapeutic approaches designed to augment T and B cell mediated killing of tumor cells has met with clinical success in recent years suggesting…”
    Get full text
    Journal Article
  3. 3

    Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells by Zhou, Hong, Marks, John W, Hittelman, Walter N, Yagita, Hideo, Cheung, Lawrence H, Rosenblum, Michael G, Winkles, Jeffrey A

    Published in Molecular cancer therapeutics (01-07-2011)
    “…TNF-like weak inducer of apoptosis (TWEAK) and fibroblast growth factor (FGF)-inducible 14 (Fn14) are a TNF superfamily ligand-receptor pair involved in many…”
    Get full text
    Journal Article
  4. 4

    Antitumor Activity of a Humanized, Bivalent Immunotoxin Targeting Fn14-Positive Solid Tumors by HONG ZHOU, HITTELMAN, Walter N, YAGITA, Hideo, CHEUNG, Lawrence H, MARTIN, Stuart S, WINKLES, Jeffrey A, ROSENBLUM, Michael G

    Published in Cancer research (Chicago, Ill.) (15-07-2013)
    “…The TNF-like weak inducer of apoptosis (TWEAK; TNFSF12) receptor Fn14 (TNFRSF12A) is expressed at low levels in normal tissues but frequently highly expressed…”
    Get full text
    Journal Article
  5. 5

    Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B by Alvarez de Cienfuegos, Ana, Cheung, Lawrence H, Mohamedali, Khalid A, Whitsett, Timothy G, Winkles, Jeffrey A, Hittelman, Walter N, Rosenblum, Michael G

    Published in Journal for immunotherapy of cancer (01-09-2020)
    “…Antibody-drug conjugates are an exceptional and useful therapeutic tool for multiple diseases, particularly for cancer treatment. We previously showed that the…”
    Get full text
    Journal Article
  6. 6

    Construction and Characterization of Novel, Recombinant Immunotoxins Targeting the Her2/neu Oncogene Product: In vitro and In vivo Studies by YU CAO, MARKS, James D, MARKS, John W, CHEUNG, Lawrence H, KIM, Sehoon, ROSENBLUM, Michael G

    Published in Cancer research (Chicago, Ill.) (01-12-2009)
    “…The goal of this study was to characterize a series of anti-Her2/neu immunotoxin constructs to identify how different antibodies and linker choices affect the…”
    Get full text
    Journal Article
  7. 7

    Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel by Selbo, Pål K, Rosenblum, Michael G, Cheung, Lawrence H, Zhang, Wendy, Berg, Kristian

    Published in PloS one (19-08-2009)
    “…There is a need for drug delivery systems (DDS) that can enhance cytosolic delivery of anti-cancer drugs trapped in the endo-lysosomal compartments. Exposure…”
    Get full text
    Journal Article
  8. 8

    Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors by Yuan, Xiaoqin, Lin, Xinjian, Manorek, Gerald, Kanatani, Isao, Cheung, Lawrence H, Rosenblum, Michael G, Howell, Stephen B

    Published in Molecular cancer therapeutics (01-07-2009)
    “…Using gene expression profiling, others and we have recently found that claudin-3 ( CLDN3 ) and claudin-4 ( CLDN4 ) are two of the most highly and consistently…”
    Get full text
    Journal Article
  9. 9

    The rGel/BLyS Fusion Toxin Inhibits Diffuse Large B-cell Lymphoma Growth In Vitro and In Vivo by Lyu, Mi-Ae, Rai, Deepak, Ahn, Kwang Seok, Sung, Bokyung, Cheung, Lawrence H., Marks, John W., Aggarwal, Bharat B., Aguiar, Ricardo C.T., Gandhi, Varsha, Rosenblum, Michael G.

    Published in Neoplasia (New York, N.Y.) (01-05-2010)
    “…Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of B-cell non-Hodgkin lymphoma (NHL) and accounts for 30%to 40%of NHL. Molecules targeting…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Cytotoxicity of VEGF121/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2 by Mohamedali, Khalid A, Ran, Sophia, Gomez-Manzano, Candelaria, Ramdas, Latha, Xu, Jing, Kim, Sehoon, Cheung, Lawrence H, Hittelman, Walter N, Zhang, Wei, Waltenberger, Johannes, Thorpe, Philip E, Rosenblum, Michael G

    Published in BMC cancer (17-08-2011)
    “…Abstract Background: The fusion protein VEGF121 /rGel composed of the growth factor VEGF121 and the plant toxin gelonin targets the tumor neovasculature and…”
    Get full text
    Journal Article
  12. 12
  13. 13

    The Antimelanoma Immunocytokine scFvMEL/TNF Shows Reduced Toxicity and Potent Antitumor Activity against Human Tumor Xenografts by Liu, Yuying, Zhang, Weihe, Cheung, Lawrence H., Niu, Ting, Wu, Qingping, Li, Chun, Van Pelt, Carolyn S., Rosenblum, Michael G.

    Published in Neoplasia (New York, N.Y.) (01-05-2006)
    “…The immunocytokine scFvMEL/TNF, a fusion protein composed of human tumor necrosis factor (TNF) and a single-chain Fv antibody (scFv) scFvMEL targeting the…”
    Get full text
    Journal Article
  14. 14

    Targeted Apoptosis Activation with GrB/scFvMEL Modulates Melanoma Growth, Metastatic Spread, Chemosensitivity, and Radiosensitivity by Liu, Yuying, Zhang, Weihe, Niu, Ting, Cheung, Lawrence H., Munshi, Anupama, Meyn, Raymond E., Rosenblum, Michael G.

    Published in Neoplasia (New York, N.Y.) (01-02-2006)
    “…GrB/scFvMEL, a fusion protein composed of human granzyme B (GrB) and the single-chain antibody scFvMEL, targets melanoma gp240 antigen and exerts impressive…”
    Get full text
    Journal Article
  15. 15

    Characterization and Mechanistic Studies of a Novel Melanoma-Targeting Construct Containing IκBa for Specific Inhibition of Nuclear Factor-κB Activity by Zhou, Hong, Liu, Yuying, Cheung, Lawrence H., Kim, Sehoon, Zhang, Weihe, Mohamedali, Khalid A., Anand, Preetha, Hittelman, Walter N., Aggarwal, Bharat B., Rosenblum, Michael G.

    Published in Neoplasia (New York, N.Y.) (01-10-2010)
    “…The transcription factor nuclear factor-κB (NF-κB) is a central mediator of growth and homeostasis for both normal and neoplastic cells. IκBα is the natural…”
    Get full text
    Journal Article
  16. 16

    Light-enhanced VEGF121/rGel: A tumor targeted modality with vascular and immune-mediated efficacy by Weyergang, Anette, Fremstedal, Ane S., Skarpen, Ellen, Peng, Qian, Mohamedali, Khalid A., Eng, Marius S., Cheung, Lawrence H., Rosenblum, Michael G., Waltenberger, Johannes, Berg, Kristian

    Published in Journal of controlled release (28-10-2018)
    “…Interactions between stromal cells and tumor cells pay a major role in cancer growth and progression. This is reflected in the composition of anticancer drugs…”
    Get full text
    Journal Article
  17. 17

    Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents by Liu, Yuying, Cheung, Lawrence H, Hittelman, Walter N, Rosenblum, Michael G

    Published in Molecular cancer therapeutics (01-12-2003)
    “…The serine protease granzyme B (GrB, 25 kDa) can initiate apoptosis by multiple mechanisms including directly activating caspases, inducing DNA fragmentation,…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin by Weyergang, Anette, Cheung, Lawrence H, Rosenblum, Michael G, Mohamedali, Khalid A, Peng, Qian, Waltenberger, Johannes, Berg, Kristian

    Published in Journal of controlled release (28-04-2014)
    “…Vascular targeting for cancer is increasingly recognized as a therapeutic strategy although the lack of objective responses and the development of resistance…”
    Get full text
    Journal Article
  20. 20